Hubei Guangji Pharmaceutical Co Ltd (000952) - Total Liabilities
Based on the latest financial reports, Hubei Guangji Pharmaceutical Co Ltd (000952) has total liabilities worth CN¥1.62 Billion CNY (≈ $236.64 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Hubei Guangji Pharmaceutical Co Ltd (000952) cash conversion ratio to assess how effectively this company generates cash.
Hubei Guangji Pharmaceutical Co Ltd - Total Liabilities Trend (1996–2024)
This chart illustrates how Hubei Guangji Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check 000952 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Hubei Guangji Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Hubei Guangji Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Delta Plus Group SA
PA:ALDLT
|
France | €261.79 Million |
|
Linhai Co Ltd
SHG:600099
|
China | CN¥608.04 Million |
|
Zhubo Design
SHE:300564
|
China | CN¥339.10 Million |
|
medmix AG
SW:MEDX
|
Switzerland | CHF536.50 Million |
|
Fittech Co Ltd
TW:6706
|
Taiwan | NT$3.37 Billion |
|
Daeduck Co. Ltd.
KO:008060
|
Korea | ₩338.17 Billion |
|
SGL Carbon SE
XETRA:SGL
|
Germany | €714.90 Million |
|
General Accident PLC
LSE:GACA
|
UK | GBX32.00 Million |
Liability Composition Analysis (1996–2024)
This chart breaks down Hubei Guangji Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Hubei Guangji Pharmaceutical Co Ltd.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.67 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.68 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.63 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hubei Guangji Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hubei Guangji Pharmaceutical Co Ltd (1996–2024)
The table below shows the annual total liabilities of Hubei Guangji Pharmaceutical Co Ltd from 1996 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.72 Billion ≈ $251.31 Million |
+4.91% |
| 2023-12-31 | CN¥1.64 Billion ≈ $239.55 Million |
+67.52% |
| 2022-12-31 | CN¥977.25 Million ≈ $143.00 Million |
+63.39% |
| 2021-12-31 | CN¥598.09 Million ≈ $87.52 Million |
-2.55% |
| 2020-12-31 | CN¥613.75 Million ≈ $89.81 Million |
-23.49% |
| 2019-12-31 | CN¥802.21 Million ≈ $117.39 Million |
-1.25% |
| 2018-12-31 | CN¥812.33 Million ≈ $118.87 Million |
-7.34% |
| 2017-12-31 | CN¥876.65 Million ≈ $128.28 Million |
-10.06% |
| 2016-12-31 | CN¥974.70 Million ≈ $142.63 Million |
-11.94% |
| 2015-12-31 | CN¥1.11 Billion ≈ $161.97 Million |
+2.77% |
| 2014-12-31 | CN¥1.08 Billion ≈ $157.60 Million |
+31.86% |
| 2013-12-31 | CN¥816.78 Million ≈ $119.52 Million |
+2.62% |
| 2012-12-31 | CN¥795.93 Million ≈ $116.47 Million |
+23.77% |
| 2011-12-31 | CN¥643.07 Million ≈ $94.10 Million |
+17.98% |
| 2010-12-31 | CN¥545.06 Million ≈ $79.76 Million |
+11.94% |
| 2009-12-31 | CN¥486.93 Million ≈ $71.25 Million |
+23.03% |
| 2008-12-31 | CN¥395.78 Million ≈ $57.92 Million |
+21.49% |
| 2007-12-31 | CN¥325.76 Million ≈ $47.67 Million |
+5.99% |
| 2006-12-31 | CN¥307.34 Million ≈ $44.97 Million |
-12.36% |
| 2005-12-31 | CN¥350.68 Million ≈ $51.32 Million |
-9.79% |
| 2004-12-31 | CN¥388.76 Million ≈ $56.89 Million |
+10.32% |
| 2003-12-31 | CN¥352.38 Million ≈ $51.56 Million |
+12.56% |
| 2002-12-31 | CN¥313.05 Million ≈ $45.81 Million |
+13.85% |
| 2001-12-31 | CN¥274.96 Million ≈ $40.24 Million |
+41.24% |
| 2000-12-31 | CN¥194.67 Million ≈ $28.49 Million |
-2.41% |
| 1999-12-31 | CN¥199.49 Million ≈ $29.19 Million |
+6.79% |
| 1998-12-31 | CN¥186.80 Million ≈ $27.34 Million |
+11.96% |
| 1997-12-31 | CN¥166.84 Million ≈ $24.41 Million |
+50.69% |
| 1996-12-31 | CN¥110.72 Million ≈ $16.20 Million |
-- |
About Hubei Guangji Pharmaceutical Co Ltd
Hubei Guangji Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical raw materials, pharmaceutical preparations, and feed additives in China and internationally. It also exports its products. The company was founded in 1969 and is based in Wuxue, China.